U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Center for Drug Evaluation and Research | CDER
  5. Office of Neuroscience - Division of Anesthesiology, Addiction Medicine, and Pain Medicine (DAAP)
  1. Center for Drug Evaluation and Research | CDER

Office of Neuroscience - Division of Anesthesiology, Addiction Medicine, and Pain Medicine (DAAP)


The Division of Anesthesia, Addiction Medicine and Pain Medicine (DAAP) regulates and reviews Investigational New Drug (IND) applications and marketing applications for drug and biologic products for the treatment of Acute Pain, e.g. Surgical and procedural pain, pain due to trauma/injury, pain due to acute inflammatory processes; Chronic pain, e.g.: cancer pain, neuropathic pain, fibromyalgia, osteoarthritis pain, low back pain and addiction, e.g.: nicotine, alcohol, stimulants, opioids. DAAP also regulates the drug product classes that are used in surgical, procedural or ICU settings to provide patient comfort and/or ease of treatment, e.g.: general anesthetics, local anesthetics, dental anesthetics, topical anesthetics, neuromuscular-blocking agents and neuromuscular-blocker reversal agents.

Division Director: Rigoberto Roca, M.D.
Deputy Director: Silvana Borges, M.D. (Acting)
Deputy Director for Safety: Mark Liberatore, Pharm.D.
Associate Director for Addiction Medicine: Celia Winchell, M.D.
Associate Director for Pain Medicine: Joette Meyer, M.D.
Associate Director for Anesthesiology: Alla T. Bazini, M.D.
Associate Director for Labeling: Lisa Basham, M.S.
Associate Director for Opioid Policy Issues: Megan Moncur, M.S.
Associate Director for Special Projects: Allison Lin, Ph.D., Pharm.D.
Safety Regulatory Project Manager: Jessica Voqui, Pharm.D.
Regulatory Operations
Chief, Project Management Staff:
Matthew Sullivan, M.S., RAC and Swati Patwardhan, M.S., RAC

The Division of Anesthesiology, Addiction Medicine, and Pain Medicine regulates and reviews Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics Licensing Applications (BLAs) for prescription drugs and biologics intended for the prevention, treatment, or diagnosis of conditions including:

  • Acute Pain, e.g.:
    • Surgical and procedural pain
    • Pain due to trauma/injury
    • Pain due to acute inflammatory processes
  • Chronic pain, e.g.:
    • Cancer pain
    • Neuropathic pain
    • Fibromyalgia
    • Osteoarthritis Pain
    • Low back pain
  • Addiction, e.g.:
    • Nicotine
    • Alcohol
    • Stimulants
    • Opioids

DAAP also regulates the drug product classes that are used in surgical, procedural or ICU settings to provide patient comfort and/or ease of treatment, e.g.:

  • General anesthetics
  • Local anesthetics
  • Dental anesthetics
  • Topical anesthetics
  • Neuromuscular-blocking agents and neuromuscular-blocker reversal agents

Contact Us

Mailing Address:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Anesthesiology, Addiction Medicine, and Pain Medicine (DAAP)
5901-B Ammendale Road
Beltsville, MD 20705-1266
Phone: (301) 796-2280
Fax: (301) 837-6231

Resources For You




Back to Top